natgillin/translations-raw huggingface dataset:
UpCard tabletter kan administreres sammen med eller uden mad.
UpCard tablets can be administered with or without food.
UPDRS II (в)
10.4
UPDRS III (в)
UPDRS III (c)
UPDRS Motor, част II: за разагилин 1 mg, сравнено с плацебо -2,7, 95 % CI [-3,87, -1,55]; p<0,0001; за разагилин 2 mg сравнено с плацебо -1,68, 95 % CI [-2,85, -0,51]; p=0,0050).
[-5.7, -2.7]; p<0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p<0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p<0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050).
uporaba
Intravenous use
Uporaba 75 mg klopidogrela na dan ni spremenila farmakokinetike S-varfarina ali internacionalnega normaliziranega razmerja (INR) pri bolnikih, ki so dolgotrajno prejemali varfarin.
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis.
Uporaba kumarinskega antikoagulanta v kliničnih študijah je bila povezana s povečano vrednostjo INR in gastrointestinalno krvavitvijo, nagnjenostjo h krvavitvam, hematurijo in anemijo pri bolnikih, ki so prejemali zdravilo Teysuno.
The use of coumarin-derivative anticoagulant in clinical trials has been associated with elevated INR and gastrointestinal bleeding, bleeding tendency, haematuria, and anaemia in patients receiving Teysuno therapy.
Uporaba laserske svetlobe
Laser Light Application
Uporaba laserske svetlobe
Uptake of photosensitiser
Uporaba ročnega nadomestnega sistema za dovajanje
Using the manual backup delivery system
Uporaba samega topotekana in topotekana v kombinaciji s cisplatinom je pogosto povezana s pojavom klinično pomembne trombocitopenije.
Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia.
Uporaba ustekinumaba statistično značilno zmanjša hitrost napredovanja strukturnih sprememb v primerjavi s placebom v 24. tednu, merjeno s spremembo celokupne vrednosti modificiranega rezultata vdH-S (v skupini s placebom je znašala povprečna vrednost ± SD 0,97 ± 3,85, v primerjavi z 0,40 ± 2,11 in 0,39 ± 2,40 za skupini, ki sta prejemali 45 mg (p < 0,05) oziroma 90 mg (p < 0,001) ustekinumaba).
Ustekinumab demonstrated a statistically significant decrease in the rate of progression of structural damage compared to placebo, as measured by change from baseline to week 24 in the total modified vdH-S score (mean ± SD score was 0.97 ± 3.85 in the placebo group compared with 0.40 ± 2.11 and 0.39 ± 2.40 in the ustekinumab 45 mg (p < 0.05) and 90 mg (p < 0.001) groups, respectively).
Uporaba v obdobju brejosti, laktacije ali nesnosti
Use during pregnancy, lactation or lay
Uporaba zdravila INOmax se v obdobju nosečnosti in dojenja ne priporoča.
INOmax is not recommended for use during pregnancy and breastfeeding.
Uporaba zdravila PhotoBarr skupaj s hrano in pijačo
Using PhotoBarr with food and drink
Uporaba zdravila Stelara ni priporočljiva med nosečnostjo.
It is preferable to avoid the use of Stelara in pregnancy.
Uporaba zdravila Topotekan Teva pri bolnikih s hudo okvaro ledvic se ne priporoča. če imate težave z jetri.
The use of Topotecan Teva is not recommended in patients with severe renal impairment; if you have liver problems.
uporabe
(Invented) name
Uporabe zdravila Pramipeksol Accord pri otrocih in mladostnikih, mlajših od 18 let, ne priporočamo.
Pramipexole Accord is not recommended for use in children or adolescents under 18 years.
Uporabi pemetrekseda med nosečnostjo se izogibamo.
The use of pemetrexed should be avoided during pregnancy.
Uporabite inaktivirano cepivo, če to obstaja (poliomielitis) (glejte poglavje 4.4).
Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4).
Uporabite lahko le infuzijske komplete, opremljene z linijskim sterilnim, nepirogenim filtrom, ki minimalno veže beljakovine (velikost por 0,2 mikrometra).
Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer).
Uporablja se:
It is used:
Uporabljena je naslednja običajna razvrstitev: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do <1/10), občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do <1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Uporabljene brizge zavrzite v za to namenjene posode za odstranjevanje ostrih predmetov, ki so narejene tako, da preprečujejo vbod z iglo (glejte Sliko 8).
Used syringes should be placed in a puncture-resistant container, like a sharps container (see Figure 8).
Uporabljene igle in brizge zavrzite v za to namenjene posode za odstranjevanje ostrih predmetov, ki so narejene tako, da preprečujejo vbod z iglo.
Used syringes and needles should be placed in a puncture-resistant container, like a sharps container.
Uporabljenih jeklenk ne zavrzite.
Do not discard used gas cylinders.
Uporabo zdravila INOmax prekinite po znatnem zmanjšanju podpore dihanju oziroma po 96 urah zdravljenja.
Attempts to wean INOmax should be made after the ventilator support is substantially decreased or after 96 hours of therapy.
Upozornenia a opatrenia
Warnings and precautions
Upozornění a opatření
Warning and precautions
Upozornění a opatření
Warnings and precautions
Upozorněte okamžitě svého lékaře, pokud vám bude tyto léky předepisovat.
Tell your doctor at once if any of these apply to you.
Upozorněte svého lékaře, pokud užíváte sildenafil k léčbě poruch erekce.
Tell your doctor if you are using sildenafil for the treatment of erectile dysfunction.
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za gimeracil/oteracil monokalij/tegafur je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Taking into account the PRAC Assessment Report on the PSUR(s) for gimeracil / oteracil monopotassium / tegafur, the scientific conclusions of CHMP are as follows:
Upoštevati morate vse predpise o ravnanju s tlačnimi jeklenkami.
All regulations concerning handling of pressurised gas cylinders must be followed.
Upoštevati morate vse predpise o ravnanju s tlačnimi posodami.
All regulations concerning handling of pressure vessels must be followed.
Upp till 30 % av emtricitabindosen kan elimineras med hemodialys.
Up to 30% of the emtricitabine dose can be removed by haemodialysis.
UPPGIFTER SOM SKA FINNAS PÅ BLISTER ELLER STRIPS
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
UPPGIFTER SOM SKA FINNAS PÅ DEN YTTRE FÖRPACKNINGEN
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
UPPGIFTER SOM SKA FINNAS PÅ SMÅ INRE LÄKEMEDELSFÖRPACKNINGAR
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
UPPGIFTER SOM SKA FINNAS PÅ YTTRE FÖRPACKNINGEN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
UPPGIFTER SOM SKALL FINNAS PÅ BLISTER ELLER STRIPS
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
UPPGIFTER SOM SKALL FINNAS PÅ DEN INRE FÖRPACKNINGEN
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
UPPGIFTER SOM SKALL FINNAS PÅ DEN YTTRE FÖRPACKNINGEN
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
UPPGIFTER SOM SKALL FINNAS PÅ DEN YTTRE FÖRPACKNINGEN‌
PARTICULARS TO APPEAR ON THE OUTER PACKAGE‌
UPPGIFTER SOM SKALL FINNAS PÅ SMÅ INRE LÄKEMEDELSFÖRPACKNINGAR
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
UPPGIFTER SOM SKALL FINNAS PÅ YTTRE FÖRPACKNINGEN OCH PÅ INNERFÖRPACKNINGEN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
upphöjda kliande hudutslag (”nässelfeber”) rodnad, smärta eller svullnad vid stället där Zavicefta gavs i en ven feber
raised itchy skin rash (“hives”) redness, pain or swelling where Zavicefta was given into a vein fever
Upravljanje vozil in strojev
Driving and using machines
Uptravi 1 000 микрограма филмирана таблетка:
Uptravi 1,000 microgram film-coated tablet
Uptravi 1 000 микрограма филмирани таблетки
Uptravi 1,000 microgram film-coated tablets
Uptravi 1 000 микрограма филмирани таблетки: Кръгли, оранжеви, филмирани таблетки с вдлъбнато релефно означение “10” от едната страна.
Uptravi 1,000 microgram film-coated tablets: Round, orange, film-coated tablets with “10” marked on one side.
Uptravi 1 200 микрограма филмирана таблетка:
Uptravi 1,200 microgram film-coated tablet
Uptravi 1 200 микрограма филмирани таблетки
Uptravi 1,200 microgram film-coated tablets
Uptravi 1 200 микрограма филмирани таблетки
Uptravi 600 microgram film-coated tablets.
Uptravi 1 200 микрограма филмирани таблетки: Кръгли, тъмнолилави, филмирани таблетки с вдлъбнато релефно означение “12” от едната страна.
Uptravi 1,200 microgram film-coated tablets: Round, dark-violet, film-coated tablets with “12” marked on one side.
Uptravi 1 400 микрограма филмирана таблетка:
Uptravi 1,400 microgram film-coated tablet
Uptravi 1 400 микрограма филмирани таблетки
Uptravi 1,400 microgram film-coated tablets
Uptravi 1 400 микрограма филмирани таблетки: Кръгли, тъмножълти, филмирани таблетки с вдлъбнато релефно означение “14” от едната страна.
Uptravi 1,400 microgram film-coated tablets: Round, dark-yellow, film-coated tablets with “14” marked on one side.
Uptravi 1 600 микрограма филмирана таблетка:
Uptravi 1,600 microgram film-coated tablet
Uptravi 1 600 микрограма филмирани таблетки
Uptravi 1,600 microgram film-coated tablets
Uptravi 1 600 микрограма филмирани таблетки: Кръгли, кафяви, филмирани таблетки с вдлъбнато релефно означение “16” от едната страна.
Uptravi 1,600 microgram film-coated tablets: Round, brown, film-coated tablets with “16” marked on one side.
Uptravi 200 микрограма Uptravi 400 микрограма Uptravi 600 микрограма Uptravi 800 микрограма Uptravi 1 000 микрограма Uptravi 1 200 микрограма Uptravi 1 400 микрограма Uptravi 1 600 микрограма
Uptravi 200 microgram Uptravi 400 microgram Uptravi 600 microgram Uptravi 800 microgram Uptravi 1,000 microgram Uptravi 1,200 microgram Uptravi 1,400 microgram Uptravi 1,600 microgram
Uptravi 200 микрограма таблетки Uptravi 400 микрограма таблетки Uptravi 600 микрограма таблетки Uptravi 800 микрограма таблетки Uptravi 1 000 микрограма таблетки Uptravi 1 200 микрограма таблетки Uptravi 1 400 микрограма таблетки Uptravi 1 600 микрограма таблетки
Uptravi 200 microgram tablets Uptravi 400 microgram tablets Uptravi 600 microgram tablets Uptravi 800 microgram tablets Uptravi 1,000 microgram tablets Uptravi 1,200 microgram tablets Uptravi 1,400 microgram tablets Uptravi 1,600 microgram tablets
Uptravi 200 микрограма филмирана таблетка:
Uptravi 200 microgram film-coated tablet
Uptravi 200 микрограма филмирани таблетки Uptravi 400 микрограма филмирани таблетки Uptravi 600 микрограма филмирани таблетки Uptravi 800 микрограма филмирани таблетки Uptravi 1 000 микрограма филмирани таблетки Uptravi 1 200 микрограма филмирани таблетки Uptravi 1 400 микрограма филмирани таблетки Uptravi 1 600 микрограма филмирани таблетки
Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1,000 microgram film-coated tablets Uptravi 1,200 microgram film-coated tablets Uptravi 1,400 microgram film-coated tablets Uptravi 1,600 microgram film-coated tablets
Uptravi 200 микрограма филмирани таблетки Uptravi 400 микрограма филмирани таблетки Uptravi 600 микрограма филмирани таблетки Uptravi 800 микрограма филмирани таблетки Uptravi 1 000 микрограма филмирани таблетки Uptravi 1 200 микрограма филмирани таблетки Uptravi 1 400 микрограма филмирани таблетки Uptravi 1 600 микрограма филмирани таблетки Селексипаг (Selexipag)
Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1,000 microgram film-coated tablets Uptravi 1,200 microgram film-coated tablets Uptravi 1,400 microgram film-coated tablets Uptravi 1,600 microgram film-coated tablets Selexipag
Uptravi 200 микрограма филмирани таблетки се предлагат в блистерни опаковки от по 10 или 60 таблетки или 140 таблетки (опаковка за титриране).
Uptravi 200 microgram film-coated tablets are supplied in blister packs of 10 or 60 tablets or 140 tablets (titration pack).
Uptravi 200 микрограма филмирани таблетки: Кръгли, бледожълти, филмирани таблетки с вдлъбнато релефно означение “2” от едната страна.
Uptravi 200 microgram film-coated tablets: Round, light-yellow, film-coated tablets with “2” marked on one side.
Uptravi 400 микрограма филмирана таблетка:
Uptravi 400 microgram film-coated tablet
Uptravi 400 микрограма филмирани таблетки
Uptravi 400 microgram film-coated tablets
Uptravi 400 микрограма филмирани таблетки: Кръгли, червени, филмирани таблетки с вдлъбнато релефно означение “4” от едната страна.
Uptravi 400 microgram film-coated tablets: Round, red, film-coated tablets with “4” marked on one side.
Uptravi 600 микрограма филмирана таблетка:
Uptravi 600 microgram film-coated tablet
Uptravi 600 микрограма филмирани таблетки: Кръгли, бледолилави, филмирани таблетки с вдлъбнато релефно означение “6” от едната страна.
Uptravi 600 microgram film-coated tablets: Round, light-violet, film-coated tablets with “6” marked on one side.
Uptravi 800 микрограма филмирана таблетка:
Uptravi 800 microgram film-coated tablet
Uptravi 800 микрограма филмирани таблетки
Uptravi 800 microgram film-coated tablets
Uptravi 800 микрограма филмирани таблетки: Кръгли, зелени, филмирани таблетки с вдлъбнато релефно означение “8” от едната страна.
Uptravi 800 microgram film-coated tablets: Round, green, film-coated tablets with “8” marked on one side.
Uptravi е показан за дългосрочно лечение на белодробна артериална хипертония (БАХ) при възрастни пациенти с функционален клас (ФК) II–III по СЗО като комбинирана терапия при пациенти, при които не се постига адекватен контрол с антагонист на ендотелиновите рецептори (ERA) и/или инхибитор на фосфодиестераза тип 5 (PDE-5), или като монотерапия при пациенти, които не са кандидати за тези лекарства.
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.
Uptravi не трябва да се прилага при пациенти, които са преживяли инфаркт през последните 6 месеца, имат тежка коронарна болест на сърцето (сърдечно заболяване, предизвикано от запушване на кръвоносните съдове, които снабдяват сърдечния мускул) или нестабилна ангина (силна гръдна болка).
Uptravi must not be used in patients who have had a heart attack within the last 6 months, severe coronary heart disease (heart disease caused by the obstruction of the blood vessels that supply the heart muscle) or unstable angina (a severe type of chest pain).
Uptravi се отпуска по лекарско предписание и лечението трябва да бъде започнато и проследявано само от лекар с опит в лечението на БАХ.
Uptravi can only be obtained with a prescription and treatment should only be started and monitored by a doctor who has experience in the treatment of PAH.
Uptravi се предлага под формата на таблетки (200; 400; 600; 800; 1000; 1200; 1400 и 1600 микрограма).
Uptravi is available as tablets (200; 400; 600; 800; 1,000; 1,200; 1,400 and 1,600 micrograms).
Uptravi филмирани таблетки от 400 микрограма, 600 микрограма, 800 микрограма, 1 000 микрограма, 1 200 микрограма, 1 400 микрограма и 1 600 микрограма
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets
Ur ett mikrobiologiskt perspektiv ska läkemedlet användas omedelbart.
From a microbiological point of view, the medicinal product should be used immediately.
ur S
0.008
ur S
0.051
URAI в рамките на 12 седмици преди скрининга, mITT анализ
URAI Within 12 Weeks Prior to Screening, mITT Analysis
URAI през предишните 12 седмици, N (%)
URAI Previous 12 Weeks, N (%)
URAI с HIV+ (или с неизвестен статус) партньор(ка) през последните 6 месеца, N (%)
URAI with HIV+ (or unknown status) Partner Previous 6 Mos, N (%)
Urea nitrogen в кръвта < 1.5 x горна граница на нормата
Blood urea nitrogen <1.5 X upper normal limit
Uriach y Compañía, S.A. Av.
J. Uriach y Compañía, S.A. Av.
Urorec 4 mg представляват жълти, матови, твърди желатинови капсули.
Urorec 4 mg are yellow, opaque, hard gelatin capsules.
Urorec 4 mg твърди капсули Silodosin
Urorec 4 mg hard capsules silodosin
Urorec 8 mg твърди капсули Silodosin
Urorec 8 mg hard capsules silodosin
Urorec 8 mg твърди капсули Urorec 4 mg твърди капсули Silodosin (Силодозин)
Urorec 8 mg hard capsules Urorec 4 mg hard capsules Silodosin
Urorec повлиява в лека или в умерена степен способността за шофиране и работа с машини.
Urorec has minor or moderate influence on the ability to drive and use machines.
Urorec се използва при възрастни мъже за лечение на симптомите на пикочната система, свързани с доброкачественото уголемяване на простатата (простатна хиперплазия), като:
Urorec is used in adult men to treat the urinary symptoms associated with benign enlargement of the prostate (prostatic hyperplasia), such as:
Urorec се предлага в опаковки с 5, 10, 20, 30, 50, 90, 100 капсули.
Urorec is available in packs containing 5, 10, 20, 30, 50, 90, 100 capsules.
urtikaaria, sügelus, erüteem
urticaria, pruritus, erythema
Urtikaria
Urticaria
Určete si cíl hubnutí
Decide on your weight loss goal
Určité formy rakoviny
Certain forms of cancer
USB
USP type
USB памет или CD ROM с цифрови изображения на проби (цифрова библиотека с изображения с висока резолюция);
USB stick or CD ROM with images of digital specimens (digital library with high resolution images).
Usposabljanje za uporabo
Training in administration
Ustekinumab je dokazano izboljšal znake in simptome ter z zdravjem povezano kakovost življenja pri pediatričnih bolnikih s psoriazo s plaki, starih 12 let in več.
Ustekinumab has been shown to improve signs and symptoms, and health related quality of life in paediatric patients 12 years and older with plaque psoriasis.
Ustekinumab je popolnoma človeško monoklonsko protitelo IgG1κ proti interlevkinu (IL)-12/23, izdelano v celični liniji mišjega plazmocitoma s tehnologijo rekombinantne DNA.
Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin (IL)-12/23 produced in a murine myeloma cell line using recombinant DNA technology.
Ustekinumab je popolnoma človeško monoklonsko protitelo IgG1κ, ki se specifično veže na p40, skupno proteinsko podenoto človeških citokinov interlevkinov (IL)-12 in IL-23.
Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23.
Ustekinumab lahko poveča tveganje za nastanek okužb in vodi do reaktivacije latentnih okužb.
Ustekinumab may have the potential to increase the risk of infections and reactivate latent infections.
Ustekinumab lahko z vezavo na podenoto p40 IL-12 in IL-23 in prekinitvijo poti citokinov Th1 in Th17, bistvenih pri patologiji psoriaze, psoriatičnega artritisa in Crohnove bolezni, spodbudi klinične učinke pri vseh boleznih.
By binding the shared p40 subunit of IL-12 and IL-23, ustekinumab may exert its clinical effects in psoriasis, psoriatic arthritis and Crohn’s disease through interruption of the Th1 and Th17 cytokine pathways, which are central to the pathology of these diseases.
Ustekinumab preprečuje vezavo p40 na receptorski protein IL-12R1, ki se nahaja na površini imunskih celic in na ta način zavira biološko aktivnost človeških interlevkinov IL-12 in IL-23.
Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by preventing p40 from binding to the IL-12R1 receptor protein expressed on the surface of immune cells.
Ustekinumab se ne more vezati na interlevkina IL-12 in IL-23, ki sta že vezana na receptorje IL-12R1 na celični površini.
Ustekinumab cannot bind to IL-12 or IL-23 that is already bound to IL-12R1 cell surface receptors.
ustekinumaba
ustekinumab
Ustrezen volumen koncentrata se redči z 9 mg/ml (0,9 %) injekcijsko raztopino natrijevega klorida ali 50 mg/ml (5 %) injekcijsko raztopino glukoze, da se doseže končno koncentracijo topotekana v raztopini za infundiranje med 25 in 50 mikrogrami/ml.
Futher dilution of the appropriate volume of the concentrate with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection to reach a final topotecan concentration of between 25 and 50 microgram/ml in the solution for infusion.
Ustrezno količino tako pripravljene raztopine morate še dodatno razredčiti z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje ali s 50 mg/ml (5 %) raztopino glukoze za injiciranje, da nastane končni pripravek s koncentracijo med 25 in 50 mikrogramov/ml.
Futher dilution of the appropriate volume of the concentrate with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection to reach a final topotecan concentration of between 25 and 50 microgram/ml in the solution for infusion.
Utförlig information om denna produkt finns tillgänglig på Europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).
Utförlig information om denna produkt finns tillgänglig på Europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).
Utförlig information om denna produkt finns tillgänglig på Europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Utförlig information om detta veterinärmedicinska läkemedel finns tillgänglig på europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).
Utförlig information om detta veterinärmedicinska läkemedel finns tillgänglig på europeiska läkemedelsmyndighetens hemsida http://www.ema.europa.eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Utg. dat.
EXP {month/year}
Utg.dat.
EXP {month/year}
Utg.dat. {månad/år}
EXP {month/year}
UTGÅNGSDATUM
EXP {month/year}
Utgångsdatumet är den sista dagen i angiven månad.
The expiry date refers to the last day of that month.
Utilsigtet selvinjektion er farlig.
Accidental self-injection is dangerous.
Utrujenost
Fatigue
utrujenost in vrtoglavica
Fatigue and vertigo
utrujenost,
Common:
utrujenost, astenija
Fatigue. asthenia
Utsättande av behandling med Emtriva hos patienter med samtidig hiv- och HBV-infektion kan vara associerad med svåra akuta exacerbationer av hepatit (se avsnitt 4.4).
Discontinuation of Emtriva therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).
Utöver biverkningarna som förekom hos vuxna var incidensen av anemi och missfärgning av huden högre i kliniska studier där hiv-infekterade pediatriska patienter ingick (se avsnitt 4.8).
In addition to the adverse reactions experienced by adults, anaemia and skin discolouration occurred more frequently in clinical trials involving HIV infected paediatric patients (see section 4.8).